Q3 2023 · 13F-HR
Paradigm Biocapital Advisors LPholdings as filed
Filed 2023-11-14 · accession 0001855655-23-000011
$1.47B
Reported value
31
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $136.1M | 9.23% | 2,025,480 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $128.5M | 8.72% | 261,443 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $106.0M | 7.19% | 2,953,122 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $96.4M | 6.54% | 7,803,600 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $75.3M | 5.11% | 1,638,147 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $73.2M | 4.97% | 3,642,307 | Common | SOLE |
| 60468T105 | MRTXEUR | MIRATI THERAPEUTICS INC | $72.7M | 4.93% | 1,668,116 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $71.9M | 4.88% | 1,384,686 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $69.4M | 4.71% | 307,314 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $64.8M | 4.40% | 2,178,737 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $59.8M | 4.06% | 1,272,279 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $56.5M | 3.83% | 3,681,747 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $55.3M | 3.75% | 2,532,972 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $52.7M | 3.58% | 912,497 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $51.0M | 3.46% | 1,491,835 | Common | SOLE |
| 02290A102 | — | AMBRX BIOPHARMA INC | $40.1M | 2.72% | 3,488,596 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $34.7M | 2.35% | 2,390,077 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $33.6M | 2.28% | 14,406,782 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $30.3M | 2.05% | 3,619,015 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $27.8M | 1.88% | 1,142,383 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $27.7M | 1.88% | 2,421,743 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $23.8M | 1.62% | 2,058,447 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $15.1M | 1.02% | 926,432 | Common | SOLE |
| 142038108 | CRBU | CARIBOU BIOSCIENCES INC | $14.1M | 0.96% | 2,944,513 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $13.7M | 0.93% | 6,461,467 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $12.6M | 0.86% | 1,081,767 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $11.1M | 0.75% | 1,212,828 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $10.1M | 0.68% | 1,358,709 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $5.1M | 0.34% | 329,100 | CALL | SOLE |
| 02290A102 | — | AMBRX BIOPHARMA INC | $2.4M | 0.16% | 209,600 | CALL | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $2.2M | 0.15% | 225,605 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.